PROX1 (D2J6J) Rabbit mAb (BSA and Azide Free) #45546
- WB
- IHC
- IF
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 85 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IHC-Immunohistochemistry
- IF-Immunofluorescence
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN or CUT&Tag assays. If you require a carrier free formulation for chromatin profiling, please contact us. Optimal dilutions/concentrations should be determined by the end user.
Formulation
Storage
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Glu567 of human PROX1 protein.
Background
Prospero homeobox protein 1 (PROX1) is a transcription factor known for its roles in organ development and lymphangiogenesis. It plays a critical role in the development of the CNS, lens, retina, liver, pancreas, and heart, and is considered to be the master regulator of the lymphatic system (1,2). PROX1 initiates the differentiation of lymphatic vasculature from the cardinal vein, where it is regulated by Sox18 (3,4). The PROX1 suppressor COUP-TFII represses the Notch pathway in venous endothelium, which prevents arterialization (4). HIF-1α and HIF-1β mediated hypoxia induces PROX1, which suggests a means of promoting lymphangiogenesis. Since the tumor microenvironment is typically hypoxic, regulation of PROX1 by hypoxia may also explain the up-regulation of this transcription factor in some cancers (2). PROX1 promotes colon cancer progression by down-regulating E-cadherin via miR-9, which promotes epithelial-mesenchymal transition (EMT) and metastasis (5). The PROX1 protein can act as a tumor suppressor in cases of hepatocellular carcinoma. PROX1 represses transcription of TWIST1, a transcription factor that promotes metastasis by binding the E-cadherin promoter. The function of PROX1 in other cancers is an area of active research (6).
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.